Cytogenix (fka CYGX)

[Paulness]

Inflammatory Disorders

Errant inflammatory response cause many human disorders and conditions. These include the formation of atherosclerotic plague the leads to heart attacks or stroke and rheumatoid arthritis. The biochemical process or "cascade" of inflammation is varied and very complex. Scientists have found common proteins and expression of certain genes in many of these inflammatory reactions. The Company has applied its technology to silence a powerful inflammation-causing gene and, has applied this sequence to a topical formulation against several inflammatory skin conditions.

Psoriasis Topical Therapeutic

The National Institutes of Health report, "Psoriasis is a chronic (long-lasting) skin disease of scaling and inflammation that affects 2 to 2.6 percent of the United States population, or between 5.8 and 7.5 million people. Although the disease occurs in all age groups, it primarily affects adults. It appears about equally in males and females. Psoriasis occurs when skin cells quickly rise from their origin below the surface of the skin and pile up on the surface before they have a chance to mature." -- http://www.niams.nih.gov/hi/topics/psoriasis/psoriafs.htm

Psoriasis is an immune system disorders that triggers an inflammatory response. CytoGenix scientists are developing a topical cream containing the company's proprietary ssDNA expression system engineered to express a sequence that silences a human gene associated with most inflammation.

The Company has scheduled initial preclinical studies to commence in 3rd quarter 2004.

Contact Dermatitis Topical Therapeutic

Eczema, also referred to as dermatitis, is an inflammatory condition of the skin. Atopic dermatitis and contact dermatitis are the most prevalent forms of eczema. It is a common skin condition affecting up to 7% of the population. Eczema can affect all ages from infants to adults. Eczema skin symptoms usually include redness, vesicles (tiny fluid filled bumps), dryness, mild swelling and most notably itching, which can be intense. As the condition progresses, the affected area can become crusty, scaly, and sometimes oozing.

CytoGenix scientists are developing a topical cream containing the company's proprietary ssDNA expression system engineered to express a sequence that silences a human gene associated with most inflammation.

The Company has scheduled initial preclinical studies to commence in 3rd quarter 2004.